Phospho-TBK1 (Ser172) Antibody - #AF8190

>>奖励金 进行中>>
(43)   (32)  
产品: 磷酸化 TBK1 (Ser172) 抗体
货号: AF8190
描述: Rabbit polyclonal antibody to Phospho-TBK1 (Ser172)
应用: WB IHC
文献验证: WB, IHC
反应: Human, Mouse, Rat
预测: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
蛋白ID: Q9UHD2
RRID: AB_2840252

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1500 现货
 100ul RMB¥ 2800 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:1000-3000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospho-TBK1 (Ser172) Antibody detects endogenous levels of TBK1 only when phosphorylated at Ser172.
RRID:
AB_2840252
引用格式: Affinity Biosciences Cat# AF8190, RRID:AB_2840252.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

EC 2.7.11.1; FLJ11330; FTDALS4; NAK; NF kappa B activating kinase; NF kB activating kinase; NF-kappa-B-activating kinase; Serine/threonine protein kinase TBK 1; Serine/threonine protein kinase TBK1; Serine/threonine-protein kinase TBK1; T2K; TANK binding kinase 1; TANK-binding kinase 1; TBK 1; Tbk1; TBK1_HUMAN;

抗原和靶标

免疫原:

A synthesized peptide derived from human TBK1 around the phosphorylation site of Ser172.

基因/基因ID:
TBK1(29110)

研究领域

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

文献引用

1). A Hybrid Nanoadjuvant Simultaneously Depresses PD-L1/TGF-β1 and Activates cGAS-STING Pathway to Overcome Radio-Immunotherapy Resistance. Advanced materials (Deerfield Beach, Fla.), 2024 (PubMed: 38229577) [IF=27.4]
2). Near-infrared light-induced photothermal and immunotherapy system for lung cancer bone metastasis treatment with simultaneous bone repair. Bioactive materials, 2025 (PubMed: 40538765) [IF=18.9]
3). Inhibiting Chemotherapy Immune Tolerance and Reversing Tumor Microenvironment by Macrophage-Targeted Nanohybrid Systems for Enhancing Tumor Chemo-Immunotherapy. ADVANCED FUNCTIONAL MATERIALS, 2025 [IF=18.5]
4). X-ray preactivated reversible persistent luminescence enables photodynamic immunotherapy of deep tumors. Nature communications, 2026 (PubMed: 41865031) [IF=16.6]
5). GPAT4 sustains endoplasmic reticulum homeostasis in endocardial cells and safeguards heart development. Nature communications, 2025 (PubMed: 40199910) [IF=14.7]
6). Nanosensitizer for enhanced radiotherapy via tumor microenvironment reshaping and ROS amplification. Theranostics, 2025 [IF=13.3]
7). A manganese-based nanoplatform leveraging chemodynamic and adjuvant effects for in situ vaccination against colorectal cancer. BIOMATERIALS, 2026 [IF=12.9]
8). CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer. Cancer research, 2024 (PubMed: 38861362) [IF=12.5]
9). A trinity STING-activating nanoparticle harnesses cancer cell STING machinery for enhanced immunotherapy. Journal of controlled release : official journal of the Controlled Release Society, 2025 (PubMed: 39561945) [IF=10.8]
10). Poly (ADP-ribose) polymerase 1-targeted photosensitizer as a dual-activator of pyroptosis and the STING pathway for enhanced cancer photoimmunotherapy. Acta biomaterialia, 2026 (PubMed: 41796924) [IF=9.4]
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.